|
1 2 3 4 5 6 7 8 9 10
далее 7-1090 8 Johnson M Bleeding, clotting and cancer Clin Oncol, 1997, 9, 294-301 9 Bick R Cancer-associated thrombosis N EngI J Med , 2003, 349 (2), 109-Ц1 10 Gordon S Cross В An enzyme-linked immunosorbent assay for cancer procoag" ulant and its potential as a new tumor marker Cancer Res , 1990, 50, 5229 5234 11 Otten H , Mathijssen J , ten Cdte H et al Symptomatic venous thromboembolism in cancer patients treated with chemotherapy an underestimated phenomenon Arch Intern Med , 2004, 164 (2), 190-194 12 Home M , Figg W Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide m patients with metastatic androgenindependent prostate cancer Pharmacotherapy 2003 23 (3), 315-318 13 Ricklcs F Shoji M Abe К The role of the hemostatic system in tumor growth, metastasis, and angiogenesis tissue factor is a bifunctional molecule capable of inducing both fibrin deposition and afigiogenesis in cancer Int J Hematol, 2001, 73 (2), 145-150. 14 Yu J , May L , Klement P et al Oncogenes as regulators of tissue factor expression in cancer implications for tumor angiogenesis and anti-cancer therapy Semm Thromb Hemost 2004 30 (1), 21-30 15 Chen J , Bierhaus A , Schiekofer S et al Tissue factor-a receptor involved in the control of cellular properties, including angiogenesis Thromb Haemost, 2001, 86 (1) 334-345 16 Wojtukiewicz M , Sierko E , Rak J Contribution of the hemostatic system to angiogenesis in cancer Semm Thromb Hemost, 2004, 30 (1), 5-20 17 Staton С , Brown N J Lewis С The role of fibnnogen and related fragments in tumour angiogenesis and metastasis Expert Opm Biol Ther 2003, 3 (7), 11051120 18 Kakkar A , Levme M , Pmedo H et al Venous thrombosis in cancer patients insights from the FRONTLINE survey Oncologist, 2003 8 (4), 381-388 19 Geerts W , Pmeo G , Heit J et al Prevention of venous thromboembolism The Seventh ACCP Conference on Antlthrombotic and Thrombolytic Therapy Chest, 2004, 126, 338S-400S 20 Pezzuoh G , Nen Semen G , Settembnm P et al Prophylaxis of fatal pulmonary embolism in general surgery using low-molecular-weight hepann Cy 216 a multicentre double-blind randomized, controlled, clinical trial versus placebo (STEP) Int Surg , 1989, 74 205-210 21 Rasmussen M Preventing thromboembollc complications in cancer patients after surgery a role for prolonged thromboprophylaxis Cancer Treat Rev , 2002, 28, 141-144 22 Bergqvist D , Burmark U , Flordal P et al Low molecular weight hepann started before surgery as prophylaxis against deep vein thrombosis 2500 versus 5000 Xal units m 2070 patients Br J Surg 1995, 82, 496-501 23 Bergqvist D , Agnelh G , Cohen A et al Duration of prophylaxis against venous " thromboembolism with enoxapann after surgery for cancer N EngI J Med , 2002, 346, 975-980 24 Rajan R , Gafm A , Levme M et al Very low-dose warfarin prophylaxis to prevent thromboembolism in women with metastic breast cancer receiving chemotherapy an economic evaluation J Clin Oncol, 1995, 13, 42-46 25 Heit J , Silvers далее ...
|
